DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Photodynamic therapy with verteporfin combined with subconjunctival injection of bevacizumab for corneal neovascularization.

Author(s): You IC, Im SK, Lee SH, Yoon KC

Affiliation(s): Department of Ophthalmology, Chonnam National University Medical School and Hospital, Gwangju, Korea.

Publication date & source: 2011-01, Cornea., 30(1):30-3.

Publication type: Research Support, Non-U.S. Gov't

PURPOSE: To investigate the efficacy of combined photodynamic therapy with verteporfin and subconjunctival injection of bevacizumab for the treatment of patients with corneal neovascularization. METHODS: Twelve eyes of 12 patients with stable corneal neovascularization who were refractory to conventional treatment were treated with photodynamic therapy with verteporfin (6 mg/m) and subconjunctival injection of bevacizumab (2.5 mg/0.1 mL). Anterior segment photography was performed before and after treatment. Best-corrected visual acuity, cumulative length of corneal blood vessels, and area of corneal neovascularization were measured. RESULTS: From 1 week to 1 month after treatment, all eyes showed a notable decrease in corneal neovascularization and evidence of vascular thrombosis. At the 6-month and 1-year follow-ups, complete vascular occlusion was achieved in 8 eyes (66.7%) and partial occlusion was achieved in 3 eyes (25.0%). One eye (8.3%) showed revascularization after temporary occlusion. No ocular complications or systemic events developed. CONCLUSIONS: Photodynamic therapy with verteporfin combined with subconjunctival injection of bevacizumab seems to be effective for the treatment of corneal neovascularization.

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017